Drug intelligence / Profile preview

NEO-002

Development stage: Preclinical
Lead developer: NeonMind Biosciences
Modality: Small Molecules

Overview

NEO-002 is a drug candidate from NeonMind that utilizes low-dose psilocybin to target obesity by acting as an agonist at the **5-HT2C receptor**, which regulates appetite and food intake. Preclinical studies in obese animal models demonstrated its efficacy in reducing weight gain, supporting its potential as a novel psychedelic-based therapy for weight management.[1][3][7]

Targets

HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on NEO-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEO-002.

Explore the full profile